BioToxTech Co

BioToxTech Co EBIT Margin

The EBIT Margin (Operating Margin) of BioToxTech Co (086040.KQ) as of Nov 19, 2026 is -10.23 %. In the previous year, EBIT Margin (Operating Margin) was -13.22 % — a change of -22.60% (higher).

EBIT Margin

-10.23 %

YoY

-22.60%

Last updated:

EBIT Margin (Operating Margin) of BioToxTech Co is 2025 -10.23 % . EBIT Margin (Operating Margin) of BioToxTech Co was 2024 -13.22 % . It decreases by -22.60% higher compared to the previous year.

For BioToxTech Co, the operating (EBIT) margin of -10.2% is down versus 12.7% a few years ago.

The BioToxTech Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
0.26 KRW
Jan 1, 2019
-5.07 KRW
Jan 1, 2020
2.03 KRW
Jan 1, 2021
12.71 KRW
Jan 1, 2022
2.63 KRW
Jan 1, 2023
-25.20 KRW
Jan 1, 2024
-13.22 KRW
Jan 1, 2025
-10.23 KRW
The BioToxTech Co EBIT Margin history
YEAREBIT MarginYoY
-10.23 %-22.60%
-13.22 %-47.56%
-25.20 %-1,059.80%
2.63 %-79.33%
12.71 %+524.81%
2.03 %-140.12%
-5.07 %-2,055.51%
0.26 %-96.97%
8.55 %-6.15%
9.11 %-135.37%
-25.76 %-16.38%
-30.80 %-214,091.67%
0.01 %-93.62%
0.23 %+52.64%
0.15 %-20.85%
0.19 %-405.73%
-0.06 %-160.01%
0.10 %+11.71%
0.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

EBIT Margin (Operating Margin) of BioToxTech Co is -10.23 % in 2025.

EBIT Margin (Operating Margin) of BioToxTech Co changed from -13.22 % to -10.23 %, representing a -22.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BioToxTech Co

All Key Metrics — BioToxTech Co